Endothelin receptor antagonists in congestive heart failure: A new therapeutic principle for the future?

Journal of the American College of Cardiology

Volumn 37, Issue 6, 2001, Pages 1493-1505

  Lu, Tse Min ^a   Tai, Ching Tai ^a,b   Hsieh, Ming Hsiung ^a   Tsai, Chin Feng ^a   Lin, Yung Kuo ^b   Yu, Wen Chung ^a,b   Tsao, Hsuan Ming ^b   Lee, Shih Huang ^a   Ding, Yu An ^a,b   Chang, Mau Song ^a,b   Chen, Shih Ann ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 3 [4 [3 (3 METHOXY 5 METHYL 2 PYRAZINYLSULFAMOYL) 2 PYRIDYL]PHENYL] 2,2 DIMETHYLPROPIONIC ACID; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; BMS 193884; BOSENTAN; CLAZOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N ACETYL 10,11 DIHYDRO 5H DIBENZO[A,D]CYCLOHEPTEN 5 YLGLYCYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; N ACETYL 3,3 DIPHENYL DEXTRO ALANYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; TAK 044;

CELL PROLIFERATION; CONGESTIVE HEART FAILURE; DRUG EFFECT; EXERCISE TOLERANCE; HEART LEFT VENTRICLE FUNCTION; HEART OUTPUT; HUMAN; HUMAN CELL; KIDNEY FUNCTION; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; SODIUM RETENTION; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; WATER RETENTION;

ANTIHYPERTENSIVE AGENTS; ENDOTHELIN-1; FORECASTING; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; INFUSIONS, INTRAVENOUS; MYOCARDIAL CONTRACTION; PEPTIDES, CYCLIC; PHENYLPROPIONATES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PYRIMIDINES; RECEPTORS, ENDOTHELIN; SULFONAMIDES; TIME FACTORS; VASCULAR RESISTANCE; VASOCONSTRICTION; VENTRICULAR FUNCTION, LEFT;

EID: 0035031967     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(01)01210-4     Document Type: Review

References (228)

1. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
2. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells
3. Epidemiology of heart failure in the United States
4. The epidemiology of heart failure: The Framingham study
5. The natural history of congestive heart failure: The Framingham study
6. Phosphoramidon, a metalloproteinase inhibitor, suppresses the secretion of endothelin-1 from cultured endothelial cells by inhibiting a big endothelin-1 converting enzyme
7. Purification and characterization of endothelin-converting enzyme from rat lung
8. Purification and characterization of a phosphoramidon-sensitive endothelin-converting enzyme in porcine aortic endothelium
9. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells
10. The human preproendothelin-1 gene: Complete nucleotide sequence and regulation of expression
11. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes
12. Immunological and structural characterization of sarafotoxin/endothelin family of peptides
13. Three apparent receptor subtypes for the endothelin/sarafotoxin family
14. Sarafotoxin, a novel vasoconstrictor peptide: Phosphoinositide hydrolysis in rat heart and brain
15. Release of endothelin from the porcine aorta: Inhibition of endothelium-derived nitric oxide
16. Oxidized low-density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium
17. Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells
18. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium
19. Acute pulmonary alveolar hypoxia increases lung and plasma endothelin-1 levels in conscious rats
20. Hypoxia increases endothelin release in bovine endothelial cells in culture, but epinephrine, norepinephrine, serotonin, histamine and angiotensin II do not
21. Production of endothelin by cultured porcine endothelial cells: Modulation by adrenaline
22. Cytokine-induced release of endothelin-1 from porcine renal epithelial cell line
23. Cytokine stimulated endothelin release from endothelial cells
24. Interleukin-2 enhances the release of endothelin-1 from the rat mesenteric artery
25. Cytokine and lipopolysaccharide stimulation of endothelin-1 release from human internal mammary artery and saphenous vein smooth-muscle cells
26. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries
27. Endothelin-1 release from endothelial cells in culture is elevated both acutely and chronically by short periods of mechanical stretch
28. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin-converting enzyme activity in vivo: Role of ETA receptors for endothelin regulation
29. Prolonged exercise causes an increase in endothelin-1 production in the heart in rats
30. Role of neutral endopeptidase in the metabolism of endothelin
31. Metabolism of endothelin-1 and big endothelin-1 by recombinant neutral endopeptidase EC.3.4.24.11
32. Endothelin is a potent mitogen for rat vascular smooth muscle cells
33. Cloning of a cDNA encoding a nonisopeptide-selective subtype of the endothelin receptor
34. Endothelin ETA and ETB receptors mediate vascular smooth muscle cell contraction
35. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels
36. Cloning and expression of a cDNA encoding an endothelin receptor
37. Cloning and functional expression of a vascular smooth muscle endothelin-1 receptor
38. Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtyper-selective ligands BQ123 and BQ3020: Evidence for expression of ET(B) receptors in human vascular smooth muscle
39. The endothelin ET(B) receptor mediates both vasodilation and vasoconstriction in vivo
40. Endothelin ET(A) and ET(B) receptors cause vasoconstriction of human resistance and capacitance vessels in vivo
41. Mobilization of intracellular calcium by endothelin in Swiss 3T3 cells
42. The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation
43. Different mobilization of calcium in endothelin-1-induced contractions in human arteries and veins: Effects of calcium antagonists
44. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm?
45. Endothelin-1-induced vasoconstriction in humans: Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor
46. Endothelln and calcium antagonists in the skin microcirculation of patients with coronary artery disease
47. Polar secretion of endothelin-1 by cultured endothelial cells
48. Radioimmunoassay of endothelin in human plasma
49. Contribution of endogenous generation of endothelin-1 to basal vascular tone
50. Exogenous effects and endogenous production of endothelin in cardiac myocytes: Potential significance in heart failure
51. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: Studies with an intracoronary ET(A) receptor antagonist
52. Identification of endothelin receptors in cultured cerebellar neurons
53. Identification of endothelin receptors in various regions of rat brain
54. Regional hemodynamic and baroreflex effects of endothelin in rats
55. Regional and cardiac hemodynamic responses to glyceryl trinitrate, acetylcholine, bradykinin and endothelin-1 in conscious rats: Effects of NG-nitro-L-arginine methyl ester
56. Different effects of low and high doses of endothelin on hemodynamics and hormones in the normotensive conscious dog
57. Cardiovascular and endocrine effects of endothelin-1 at pathophysiological and pharmacological plasma concentrations in conscious dogs
58. Central effects of endothelin on baroreflex of spontaneously hypertensive rats
59. Effects of centrally administered endothelin-3 on renal sympathetic nerve activity and renal blood flow in conscious rats
60. Suppression of baroreceptor discharge by endothelin at high carotid sinus pressure
61. Modulatory effects of endothelin on baroreflex activation in the nucleus of the solitary tract
62. Systemic and renal effect of intravenous infusion of endothelin-1 in healthy human volunteers
63. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade
64. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: Exclusive role of ETB receptors
65. Human pulmonary circulation is an important site for both clearance and production of endothelin-1
66. ETB-mediated regulation of extracellular levels of endothelin-1 in cultured human endothelial cells
67. Clearance of circulating endothelin-1 by ETB receptors in rats
68. Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: A novel autocrine function
69. Endothelin-1 as an autocrine growth factor for endothelial cells
70. Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop
71. Endothelin receptor B subtype B mediates autoinduction of endothelin-1 in rat mesangial cells
72. Aortic arch malformations and ventricular septal defect in mice deficient in endothelin-1
73. Transgenic expression of the endothelin-B receptor prevents congenital intestinal aganglionosis in a rat model of Hirschsprung disease
74. Targeted and natural (piebald-lethal) mutations of endothelin-B receptor genes produce megacolon associated with spotted coat color in mice
75. Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons
76. A homozygous mutation in the endothelin-3 gene associated with a combined Waardenburg type 2 and Hirschsprung phenotype (Shah-Waardenburg syndrome)
77. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice
78. The temporal requirement for endothelin receptor-B signaling during neural crest development
79. A potential role for endothelin-1 in human placental growth: Interactions with the insulin-like growth factor family of peptides
80. Plasma endothelin in chronic heart failure
81. Increased plasma concentrations of endothelin in congestive heart failure in humans
82. Endothelin in human congestive heart failure
83. Comparison of plasma neurohormones in congestive heart failure patients with atrial fibrillation versus patients with sinus rhythm
84. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure
85. Role of blood pressure in the development of congestive heart failure: The Framingham study
86. The progression from hypertension to congestive heart failure
87. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo: Blunted response in essential hypertension
88. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension
89. Imbalance of endothelium-derived relaxing and contracting factors: A new concept in hypertension?
90. Effect of endothelin-1 in man
91. Cardiopulmonary effects of endothelin-1 in man
92. ET-1 induces hypertrophy with enhanced expression of muscle specific genes in cultured neonatal rat cardiomyocytes
93. ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy and endothelial dysfunction in salt-sensitive hypertension
94. Endothelin-1 potentiates smooth muscle cell growth to PDGF: Role of ETA and ETB receptor blockade
95. Left ventricular hypertrophy by electrocardiogram: Prevalence, incidence and mortality in the Framingham study
96. Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam study
97. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke stroke in older adults: Cardiovascular Health Study Collaborative Research Group
98. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension
99. Increased plasma endothelin level in patients with essential hypertension
100. Age- and sex-related variation of plasma endothelin-1 concentration in normal and hypertensive subjects
101. Bosentan in essential hypertension
102. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: Reversal by ET(A)-receptor antagonist
103. Genetic variability of the ET-1 and the ETA receptor genes in essential hypertension
104. The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people
105. Polymorphisms of the endothelin-A and -B receptor genes in relation to blood pressure and myocardial infarction: The Etude Cas-Temoins sur l'Infarctus du Myocarde (ECTIM) study
106. Quantitative association between a newly identified molecular variant in the endothelin-2 gene and human essential hypertension
107. Chronic ETA-receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats
108. Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension
109. Blood pressure and vascular effects of endothelin blockade in chronic nitric oxide-deficient hypertension
110. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension
111. An overview of contemporary etiologies of congestive heart failure
112. Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents
113. Endothelin-1 inhibits nitric oxide synthesis in vascular smooth muscle cells
114. Effect of the endothelin family of peptides on human coronary artery smooth-muscle cell migration
115. Effect of endothelin-1 on neutrophil adhesion to endothelial cells and perfused heart
116. In vitro effect of endothelin-1 on collagen and ADP-induced aggregation in human whole blood and platelet rich plasma
117. Flow-induced release of endothelium-derived relaxing factor
118. Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins
119. Nitric oxide is responsible for flow-dependent dilation of human peripheral conduit arteries in vivo
120. Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine endothelial cells
121. Increased plasma endothelin-1 in heavy and light smokers
122. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis
123. Endothelin-1 and its mRNA in the wail layers of human arteries ex vivo
124. Plasma endothelin determination as a prognostic indicator of one-year mortality after acute myocardial infarction
125. Endothelinconverting enzyme expression in the rat vascular injury model and human coronary atherosclerosis
126. Tissue endothelin-converting enzyme activity correlates with cardiovascular risk factors in coronary artery disease
127. Increased tissue endothelin immunoreactivity in atherosclerotic lesions associated with acute coronary syndromes
128. Tissue endothelin-1 lmmunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina
129. TaqI polymorphism at the human preproendothelin-1 gene (EDN1)
130. TaqI identifies a four-allele DNA polymorphism of the human endothelin-1 gene (EDN1)
131. A TaqI RFLP at the EDN1 gene locus
132. A short tandem repeat polymorphism at the endothelin-1 (EDN1) locus
133. Identification of a genetic risk factor for idiopathic dilated cardiomyopathy: Involvement of a polymorphism in the endothelin-receptor type A gene
134. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice
135. Chronic endothelin-receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia
136. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease
137. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction
138. Circulating endothelin in acute ischemic syndromes
139. Plasma endothelin-1 in acute myocardial infarction with heart failure
140. Pharmacology of a nonselective ETA and ETB receptor antagonist TAK-044 and the inhibition of myocardial infarct size in rats
141. Role of endogenous endothelin in the extension of myocardial infarct size studied with the endothelin-receptor antagonist TAK-044
142. Role of endogenous endothelin in extension of rabbit myocardial infarction
143. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats
144. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion
145. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure
146. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure
147. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
148. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure
149. Altered production of endothelin-1 in the hypertrophied rat heart
150. Increased cardiac expression of endothelin-1 mRNA in ischemic heart failure in rats
151. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin-receptor antagonist. Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats
152. Increased cardiac and pulmonary endothelin-1 mRNA expression in canine pacing-induced heart failure
153. Coordinated upregulation of the cardiac endothelin system in a rat model of heart failure
154. Increased endothelin in experimental heart failure
155. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure: Marked increase in endothelin-1 production in the failing heart
156. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure
157. Plasma endothelin concentrations in humans with end stage heart failure and after heart transplantation
158. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure
159. Role of endothelin in the exercise intolerance of chronic heart failure
160. Expression of endothelin-1 and endothelin-converting enzyme-1 mRNAs and proteins in failing human hearts
161. Expression of endothelin-1, endothelin-converting enzyme and endothelin receptors in chronic heart failure
162. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension
163. Prognostic value of plasma endothelin-1 in patients with chronic heart failure
164. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure
165. Endothelin receptors in the failing and nonfailing human heart
166. Effect of endothelin-1 on exercise-induced vasodilation in normal subjects and in patients with heart failure
167. Venous endothelin-receptor function in patients with chronic heart failure
168. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure
169. Plasma endothelin during upright tilt: Relevance for orthostatic hypotension?
170. Selective impairment of baroreflex-mediated vasoconstrictor responses in patients with ventricular dysfunction
171. Elevated endothelin-1 in heart failure and loss of normal response to postural change
172. Fluid flow decreases preproendothelin mRNA levels and suppresses endothelin-1 peptide release in cultured human endothelial cells
173. Modulation of NO and endothelin by chronic increases in blood flow in canine femoral arteries
174. Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction
175. Downregulation of ET(B) receptor, but not ET(A) receptor, in congestive lung secondary to heart failure. Are marked increases in circulating endothelin-1 partly attributable to decreases in lung ET(B) receptor-mediated clearance of endothelin-1?
176. Elevated plasma endothelin concentrations in heart failure: An effect of angiotensin II?
177. Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure
178. Plasma endothelin in congestive heart failure: Effect of the ACE inhibitor fosinopril
179. Physical training improves endothelial function in patients with chronic heart failure
180. Effects of L-arginine on impaired acetylcholine-induced and ischemic vasodilation of the forearm in patients with heart failure
181. Isometric handgrip exercise increases endothelin-1 plasma levels in patients with chronic congestive heart failure
182. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure
183. Increased concentrations of tumor necrosis factor in "chachectic" patients with severe chronic heart failure
184. Spontaneous endothelin production by circulating mononuclear cells from patients with chronic heart failure but not from normal subjects
185. Comparison of the positive inotropic effects of serotonin, histamine, angiotensin II, endothelin and isoprenaline in the isolated human right atrium
186. Integrated cardiac, renal and endocrine actions of endothelin
187. Endothelin stimulates aldosterone biosynthesis by dispersed rabbit adrenocapsular cells
188. Endothelin binding to cultured calf adrenal zona glomerulosa cells and stimulation of aldosterone secretion
189. Changes in plasma renin activity and aldosterone concentration in response to endothelin injection in dogs
190. Effects of endothelin on systemic and renal hemodynamics and neuroendocrine hormones in conscious dogs
191. Effects of endothelin on renal hemodynamics and excretory functions in anesthetized dogs
192. Mechanisms involved in the stimulation of aldosterone production by angiotensin II, vasopressin and endothelin
193. Endothelin-receptor subtypes and stimulation of aldosterone secretion
194. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Group (CONSENSUS)
195. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
196. A randomized trial of beta-blockade in heart failure: The Cardiac Insufficiency BIsoprolol Study (CIBIS)
197. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)
198. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure: Acute effects of the endothelin-receptor antagonist Ro 47-0203 (bosentan)
199. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
200. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure
201. Multicenter, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure - Results of the REACH-1 trial
202. Pathophysiological role of endothelin revealed by the first orally active endothelin-receptor antagonist
203. Reversal of postischemic acute renal failure with a selective endothelin-A-receptor antagonist in the rat
204. Bosentan improves renal regional blood flow in rats with experimental congestive heart failure
205. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men
206. Comparison of the effects of selective endothelin ETA- and ETB-receptor antagonists in congestive heart failure
207. Endothelial function in chronic congestive heart failure
208. Flow-mediated arteriolar dilation is abnormal in congestive heart failure
209. Vasoconstrictor effect of endothelin-1 in human skin: Role of ETA- and ETB-receptors
210. Endothelin-B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction
211. Upregulated expression of cardiac endothelin-1 participates in myocardial cell growth in Bio14.6 Syrian cardiomyopathic hamsters
212. Mild hypoxia induces hypertrophy of cultured neonatal rat cardiomyocytes: A possible role for endogenous endothelin-1-mediated mechanism
213. Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts
214. Altered expression of isoforms of myosin heavy chain mRNA in the failing rat heart is ameliorated by chronic treatment with an endothelin receptor antagonist
215. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure
216. Comparison of the acute effects of a selective endothelin ETA and a mixed ETA/ETB-receptor antagonist in heart failure
217. Beneficial effects of long-term selective endothelin type A-receptor blockade in canine experimental heart failure
218. Concomitant endothelin-receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits: Beneficial effects on left ventricular and myocyte function
219. Chronic oral endothelin type A-receptor antagonism in experimental heart failure
220. Short-term hemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure
221. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA-receptor blockade in chronic heart failure patients treated with ACE inhibitors
222. Acute hemodynamic and neurohumoral effects of selective ETA-receptor blockade in patients with congestive heart failure
223. Improved hemodynamics with the ET(A) selective receptor antagonist BMS-I93884 in patients with heart failure
224. Clinical and hemodynamic effects of chronic selective ETA-receptor blockade in congestive heart failure (HEAT, Heart Failure ETA Receptor Blockade trial)
225. Bosentan, a dual endothelin receptor antagonist, improves exercise capacity and hemodynamics in patients with pulmonary arterial hypertension
226. Tezosentan (the first i.v. endothelin receptor A/B antagonist) reduces peripheral resistance and increases myocardial contractility despite reducing left ventricular filling (wedge) pressure in patients with congestive heart failure
227. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure